AR122913A1 - Agonistas de pirazolona del formil péptido receptor 2 - Google Patents

Agonistas de pirazolona del formil péptido receptor 2

Info

Publication number
AR122913A1
AR122913A1 ARP210101921A ARP210101921A AR122913A1 AR 122913 A1 AR122913 A1 AR 122913A1 AR P210101921 A ARP210101921 A AR P210101921A AR P210101921 A ARP210101921 A AR P210101921A AR 122913 A1 AR122913 A1 AR 122913A1
Authority
AR
Argentina
Prior art keywords
alkyl
halo
haloalkyl
substituted
hydroxy
Prior art date
Application number
ARP210101921A
Other languages
English (en)
Inventor
James A Johnson
Zulan Pi
Nicholas R Wurtz
Joanne M Smallheer
Meriah Neissel Valente
Ellen K Kick
Charles G Clark
Pravin Sudhakar Shirude
Balaji Seshadri
Amit Kumar Chattopadhyay
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR122913A1 publication Critical patent/AR122913A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
    • C07D231/46—Oxygen atom in position 3 or 5 and nitrogen atom in position 4
    • C07D231/50—Acylated on said nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La descripción se refiere a compuestos de la fórmula (1), que son agonistas del receptor del formil péptido 2 (FPR2). La divulgación también proporciona composiciones y métodos para usar los compuestos, por ejemplo, para el tratamiento de aterosclerosis, insuficiencia cardíaca, enfermedad pulmonar obstructiva crónica (EPOC) y enfermedades relacionadas. Reivindicación 1: Un compuesto de la fórmula (1) o una sal farmacéuticamente aceptable del mismo, donde: R¹ es alquilo, haloalquilo, hidroxialquilo, alcoxialquilo, alcoxicarboniloalquilo, cicloalquilo, (Ar¹)alquilo, o Ar¹; Ar¹ es cicloalquilo, un resto de fórmula (2), fenilo, piridinilo, piridazinilo, pirimidinilo, pirazinilo, pirrolilo, furanilo, tienilo, pirazolilo, isoxazolilo, isotiazolilo, imidazolilo, oxazolilo, tiazolilo, triazolilo, oxadiazolilo, o tiadiazolilo, quinolinilo, isoquinolinilo, o quinoxalinilo, y es sustituido por 0 - 2 R⁵ᵃ y 0 - 2 R⁵ᵇ; R² es alquilo o haloalquilo; R³ es fenilo o piridinilo sustituido por 1 R³ᵃ y 0 - 2 R³ᵇ; R³ᵃ es sustituyente de halo, alquilo, haloalquilo, alcoxi, alcoxi deuterado, haloalcoxi o cicloalquilo en la posición para con respecto a la fracción de pirazol-3-ona; R³ᵇ es halo, alquilo, hidroxilo o haloalquilo; o R³ᵃ y el R³ᵇ adyacente, junto con los dos átomos de carbono a los que están unidos, forman un heterociclo de 3 - 6 miembros que comprende átomos de carbono y 1 - 3 heteroátomos seleccionados de N, O, S, y sustituidos con 0 - 3 halo, hidroxi, alquilo, haloalquilo o alcoxicarbonilo; R⁴ es fenilo o piridinilo sustituido por 1 R⁴ᵃ y 0 - 2 R⁴ᵇ; R⁴ᵃ es sustituyente halo, alquilo, cicloalquilo, haloalquilo, alcoxi, haloalcoxi, o pirazolilo en la posición para con respecto a la fracción de amida; R⁴ᵇ es halo o haloalquilo; R⁵ᵃ y R⁵ᵇ son independientemente ciano, halo, alquilo, haloalquilo, alcoxialquilo, hidroxi, hidroxialquilo, alcoxi, alcoxialcoxi, hidroxialcoxi, haloalcoxi, hidroxihaloalcoxi, hidroxialcoxialcoxi, alquilosulfonilalcoxi, carboxamida, alcoxicarbonilo, alquilaminoalquilo, alcoxicarbonilalcoxi, hidroxialquilocicloalquiloalquilo, alquilsulfonilo, aminocarbonilalquilo, -NR⁷R⁸, cicloalquilo sustituido con 0 - 3 halo, hidroxi, alquilo o alcoxi, fenilo sustituido con 0 - 3 halo, hidroxi o alquilo, heterociclilo de 4 - 8 miembros que comprende átomos de carbono y 1 - 3 heteroátomos seleccionados entre N, NH, O, S, y sustituido con 0 - 3 halo, alquilo, hidroxialquilo, haloalquilo, alcoxicarbonilo o alquilsulfonilo, heterocicliloxi o heterociclilalquilo o heterociclilalcoxi, en el que el resto heterociclilo del heterocicliloxi, heterociclilalquilo y heterociclilalquilo comprende de 1 a 3 átomos de carbono. heteroátomos seleccionados entre N, NH, O, S y sustituidos con 0 - 3 halo, hidroxi, hidroxialquilo, alquilo o haloalquilo; R⁶ es hidrógeno o alquilo inferior; R⁷ y R⁸ son independientemente hidrógeno, alquilo, haloalquilo, hidroxialquilo, halohidroxialquilo, alcoxialquilo, aminocarbonilalquilo, alquilsulfonilo; alquilaminocarbonilalquilo, cicloalquilaminocarbonilalquilo, cicloalquilalquilo, hidroxicicloalquilalquilo, hidroxialquilcicloalquilalquilo, cicloalquilalquilo, cicloalquilo, en el que cada cicloalquilo está sustituido con 0 - 3 átomos de halo, hidroxi o alquilo, o heterocicloalquilo de 5 a 8 átomos de carbono seleccionados o hidroxialquilo de 1 a 8, O, S y sustituido con 0 - 3 halo, hidroxi, alquilo, haloalquilo o alcoxicarbonilo; y o R⁷ y R⁸, junto con el nitrógeno al que están unidos, forman un heterociclo de 5 - 12 miembros que comprende átomos de carbono y 0 - 3 heteroátomos adicionales seleccionados de N, O, S, y sustituidos con 0 - 5 halo, hidroxi, alquilo, alcoxi, oxo, haloalquilo, cicloalquilalquilo, hidroxialquilo, alcoxialquilo, alquilsulfonilo, alquilsulfonilalquilo, aminocarbonilo o alcoxicarbonilo.
ARP210101921A 2020-07-09 2021-07-08 Agonistas de pirazolona del formil péptido receptor 2 AR122913A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063049831P 2020-07-09 2020-07-09

Publications (1)

Publication Number Publication Date
AR122913A1 true AR122913A1 (es) 2022-10-12

Family

ID=77127111

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210101921A AR122913A1 (es) 2020-07-09 2021-07-08 Agonistas de pirazolona del formil péptido receptor 2

Country Status (15)

Country Link
US (1) US20230250063A1 (es)
EP (1) EP4178949B9 (es)
JP (1) JP2023533039A (es)
KR (1) KR20230038516A (es)
CN (1) CN115836053A (es)
AR (1) AR122913A1 (es)
AU (1) AU2021305293A1 (es)
BR (1) BR112023000344A2 (es)
CA (1) CA3185263A1 (es)
CL (1) CL2023000077A1 (es)
CO (1) CO2023000129A2 (es)
IL (1) IL299680A (es)
MX (1) MX2023000406A (es)
TW (1) TW202216669A (es)
WO (1) WO2022011083A1 (es)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0312368D0 (en) * 2003-05-30 2003-07-02 Univ Aston Novel ureido- and amido-pyrazolone derivatives

Also Published As

Publication number Publication date
AU2021305293A1 (en) 2023-03-09
EP4178949B9 (en) 2024-09-04
KR20230038516A (ko) 2023-03-20
TW202216669A (zh) 2022-05-01
IL299680A (en) 2023-03-01
EP4178949A1 (en) 2023-05-17
BR112023000344A2 (pt) 2023-01-31
CA3185263A1 (en) 2022-01-13
EP4178949B1 (en) 2024-06-19
US20230250063A1 (en) 2023-08-10
MX2023000406A (es) 2023-02-02
CO2023000129A2 (es) 2023-01-16
CL2023000077A1 (es) 2023-06-16
WO2022011083A1 (en) 2022-01-13
CN115836053A (zh) 2023-03-21
JP2023533039A (ja) 2023-08-01

Similar Documents

Publication Publication Date Title
ES2902504T3 (es) Compuestos de indol sustituidos con piridilo
ES2313283T3 (es) Derivados de heteroarilo condensados para usar inhibidores de quinasa p38`.
ES2379076T3 (es) Derivados de pirazol útiles como inhibidores de COX-I
ES2322709T3 (es) Derivados de benzamida y su uso como agentes activadores de la glucocinasa.
AU2006332124B2 (en) 3 , 5-substitgammaued piperidine compounds as renin inhibitors
ES2536191T3 (es) Derivados de sulfonamida
ES2385659T3 (es) Derivados de pirazol para tratar VIH
ES2307237T3 (es) Compuestos que ejercen efecto sobre la glucoquinasa.
ES2655855T4 (es) Derivados de piperidinil-indol y su uso como inhibidores del factor de complemento B
ES2439894T3 (es) Derivados de 3-cicloalquilaminopirrolidina como moduladores de receptores de quimioquina
ES2320008T3 (es) Compuestos de piperidina sustituidos para uso como antagonistas del receptor de histamina h3.
AU2011287574B2 (en) N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides as inhibitors of plasma kallikrein
RU2483072C2 (ru) Производные фосфоновой кислоты и их применение в качестве антагонистов рецептора p2y12
ES2525132T3 (es) Pirazoles trisustituidos como moduladores de los receptores de acetilcolina
JP2019513776A5 (es)
CA2563963A1 (en) 3-heterocyclyl-4-phenyl-triazole derivatives as inhibitors of the vasopressin v1a receptor
AR070950A1 (es) Compuestos derivados de amina, composiciones farmaceuticas de ellos, compuestos inhibidores de produccion de 11-cis-retinol y metodos para tratar enfermedades y trastornos oftalmicos
AU2008205093A1 (en) Factor Xa inhibitors
CA2612287A1 (en) Substituted arylpyrazoles for use against parasites
RU2006118326A (ru) Производное циклического амина, содержащее гетероарильный цикл
ES2287508T3 (es) Compuestos de triazol para el tratamiento de dismenorrea.
ES2651491T3 (es) Compuesto de amida heterocíclico
CA2672373A1 (en) Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
RU2006129492A (ru) Производные индола и их применение в качестве ингибиторов киназ, в частности, ингибиторов ikk2
AR051790A1 (es) Tratamiento de tuberculosis latente